Mineralys Therapeutics (MLYS) Other Non-Current Assets (2022 - 2026)

Mineralys Therapeutics has disclosed Other Non-Current Assets across 5 years of filings, most recently posting $360000.0 for Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $360000.0, down 9.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $360000.0 (down 9.32% YoY), and the FY2025 annual result was $382000.0, down 23.45% from the prior year.
• Other Non-Current Assets came in at $360000.0 for Q1 2026 at Mineralys Therapeutics, down from $382000.0 in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $1.6 million in Q4 2022 to a low of $39000.0 in Q1 2023.
• The 5-year median for Other Non-Current Assets is $380500.0 (2024), against an average of $379857.1.
• Across the five-year window, Other Non-Current Assets sank 96.87% in 2023 and jumped 878.43% in 2024, its largest moves.
• Mineralys Therapeutics' Other Non-Current Assets stood at $1.6 million in 2022, then tumbled by 96.87% to $51000.0 in 2023, then surged by 878.43% to $499000.0 in 2024, then fell by 23.45% to $382000.0 in 2025, then dropped by 5.76% to $360000.0 in 2026.
• The last three Other Non-Current Assets figures came in at $360000.0 (Q1 2026), $382000.0 (Q4 2025), and $144000.0 (Q3 2025), per Business Quant data.